Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 38 articles: HTML format

Single Articles

February 2024
1. CHELLADURAI M, Xu D, Izraely S, Ben-Menachem S, et al
   A heterodimer of alpha and beta hemoglobin chains functions as an innate anticancer agent.
   Int J Cancer. 2024;154:561-572.
   PubMed     Abstract available
   
   
   January 2024
2. VAN DUIN IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, et al
   A prediction model for response to immune checkpoint inhibition in advanced melanoma.
   Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34853.
   PubMed     Abstract available
   
   
   December 2023
3. DINTER L, Karitzky PC, Schulz A, Wurm AA, et al
   BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
   Int J Cancer. 2023 Dec 11. doi: 10.1002/ijc.34807.
   PubMed     Abstract available
   
   
   November 2023
4. HUERGO-BANOS C, Velasco V, Garate J, Fernandez R, et al
   Lipid fingerprint-based histology accurately classifies nevus, primary melanoma, and metastatic melanoma samples.
   Int J Cancer. 2023 Nov 20. doi: 10.1002/ijc.34800.
   PubMed     Abstract available
   
   
   
5. TOPE P, Morais S, El-Zein M, Franco EL, et al
   Differences in site-specific cancer incidence by individual- and area-level income in Canada from 2006 to 2015.
   Int J Cancer. 2023;153:1766-1783.
   PubMed     Abstract available
   
   
   October 2023
6. AFSHAR N, Dashti SG, Mar V, Te Marvelde L, et al
   Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data.
   Int J Cancer. 2023 Oct 12. doi: 10.1002/ijc.34752.
   PubMed     Abstract available
   
   
   September 2023
7. ZHANG J, Zhang F, Porter KI, Dakup PP, et al
   Telomere dysfunction in Tert knockout mice delays Braf(V600E) -induced melanoma development.
   Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34713.
   PubMed     Abstract available
   
   
   July 2023
8. KRETSCHMER L, Bernhard L, Leha A, Kromer C, et al
   Checkpoint blockade and BRAF/MEK therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998-2009 and 2010-2017.
   Int J Cancer. 2023;153:380-388.
   PubMed     Abstract available
   
   
   June 2023
9. FRAGALE A, Stellacci E, Romagnoli G, Licursi V, et al
   Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
   Int J Cancer. 2023 Jun 9. doi: 10.1002/ijc.34602.
   PubMed     Abstract available
   
   
   April 2023
10. 
    Erratum to "Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma".
    Int J Cancer. 2023 Apr 12. doi: 10.1002/ijc.34534.
    PubMed    
    
    
    March 2023
11. HEIKKINEN S, Demers PA, Hansen J, Jakobsen J, et al
    Incidence of cancer among Nordic police officers.
    Int J Cancer. 2023;152:1124-1136.
    PubMed     Abstract available
    
    
    February 2023
12. VAN DUIN IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, et al
    Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34479.
    PubMed     Abstract available
    
    
    
13. DE MEZA MM, Blokx WAM, Bonenkamp HJ, Blank CU, et al
    Adjuvant Treatment of In-Transit Melanoma: Narrowing the Knowledge Gap Left by Clinical Trials.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34485.
    PubMed     Abstract available
    
    
    
14. DE FALCO V, Suarato G, Napolitano R, Argenziano G, et al
    Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two Academic Italian Institutions.
    Int J Cancer. 2023 Feb 8. doi: 10.1002/ijc.34462.
    PubMed     Abstract available
    
    
    December 2022
15. KUMAR N, Papillon-Cavanagh S, Tang H, Wang S, et al
    A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.
    Int J Cancer. 2022;151:2043-2054.
    PubMed     Abstract available
    
    
    November 2022
16. JAEHN P, Bergholz A, Holmberg C
    Regional inequalities of tumour size at diagnosis in Germany: An ecological study in eight federal states.
    Int J Cancer. 2022;151:1684-1695.
    PubMed     Abstract available
    
    
    August 2022
17. SEEFRIED F, Haller L, Fukuda S, Thongmao A, et al
    Nuclear AREG affects a low-proliferative phenotype and contributes to drug resistance of melanoma.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34254.
    PubMed     Abstract available
    
    
    
18. MAHAMAT-SALEH Y, Al-Rahmoun M, Severi G, Ghiasvand R, et al
    Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC).
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34253.
    PubMed     Abstract available
    
    
    June 2022
19. ZAREMBA A, Jansen P, Murali R, Mayakonda A, et al
    Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
    Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34187.
    PubMed     Abstract available
    
    
    April 2022
20. CLAYTON B, Muneeb F, Hughes MCB, Grant ME, et al
    Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: a multi-centre study.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34020.
    PubMed     Abstract available
    
    
    January 2022
21. ELLEBAEK E, Schina A, Andersen R, Hendel HW, et al
    Clinical value of routine FDG-PET scans as a decision tool for early immunotherapy discontinuation in advanced melanoma.
    Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33926.
    PubMed     Abstract available
    
    
    
22. AAMDAL E, Jacobsen KD, Straume O, Kersten C, et al
    Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
    Int J Cancer. 2022;150:100-111.
    PubMed     Abstract available
    
    
    November 2021
23. MARLEY AR, Li M, Champion VL, Song Y, et al
    Citrus-Gene Interaction and Melanoma Risk in the UK Biobank.
    Int J Cancer. 2021 Nov 1. doi: 10.1002/ijc.33862.
    PubMed     Abstract available
    
    
    October 2021
24. LAI X, Zhou J, Wessely A, Heppt M, et al
    A disease network-based deep learning approach for characterizing melanoma.
    Int J Cancer. 2021 Oct 29. doi: 10.1002/ijc.33860.
    PubMed     Abstract available
    
    
    
25. VAN NOT OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, et al
    The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
    Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33833.
    PubMed     Abstract available
    
    
    September 2021
26. ROGAVA M, Braun AD, van der Sluis TC, Shridhar N, et al
    Tumor cell intrinsic TLR4 signaling promotes melanoma progression and metastatic dissemination.
    Int J Cancer. 2021 Sep 16. doi: 10.1002/ijc.33804.
    PubMed     Abstract available
    
    
    
27. LIU W, Liu Y, Hu C, Xu C, et al
    Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Int J Cancer. 2021;149:1369-1384.
    PubMed     Abstract available
    
    
    
28. VAN ZEIJL MCT, van den Eertwegh AJM, Wouters MWJM, de Wreede LC, et al
    Discontinuation of anti-PD-1 monotherapy in advanced melanoma - outcomes of daily clinical practice.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33800.
    PubMed    
    
    
    May 2021
29. ARROYO MUHR LS, Hultin E, Dillner J
    Transcription of Human Papillomaviruses in Non-Melanoma Skin Cancers of the Immunosuppressed.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33683.
    PubMed     Abstract available
    
    
    April 2021
30. SUN Q, Novak D, Huser L, Poelchen J, et al
    FOXD1 Promotes Dedifferentiation and Targeted Therapy Resistance in Melanoma by Regulating the Expression of CTGF.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33591.
    PubMed     Abstract available
    
    
    February 2021
31. BUCCHI L, Mancini S, Crocetti E, Dal Maso L, et al
    Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy.
    Int J Cancer. 2021;148:835-844.
    PubMed     Abstract available
    
    
    January 2021
32. KOUTROS S, Decker KL, Baris D, Pardo LA, et al
    Bladder Cancer Risk Associated with Family History of Cancer.
    Int J Cancer. 2021 Jan 27. doi: 10.1002/ijc.33486.
    PubMed     Abstract available
    
    
    
33. SACCHETTO L, Rosso S, Comber H, Bouchardy C, et al
    Skin Melanoma Deaths Within 1 Or 3 Years From Diagnosis In Europe.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33479.
    PubMed     Abstract available
    
    
    
34. MONESTIER S, Dalle S, Mortier L, Dutriaux C, et al
    Effectiveness and Safety of Nivolumab in Patients with Advanced Melanoma: A Multicenter, Observational Study.
    Int J Cancer. 2021 Jan 11. doi: 10.1002/ijc.33467.
    PubMed     Abstract available
    
    
    December 2020
35. CHOI J, Jia G, Wen W, Long J, et al
    Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants.
    Int J Cancer. 2020;147:3416-3423.
    PubMed     Abstract available
    
    
    November 2020
36. DELLAC S, Ben-Dov H, Raanan A, Saleem H, et al
    Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33401.
    PubMed     Abstract available
    
    
    October 2020
37. DAI WF, Beca J, Croxford R, Isaranuwatchai W, et al
    Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33357.
    PubMed     Abstract available
    
    
    September 2020
38. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.